In vitro and in vivo antiparasital activity against Trypanosoma cruzi of three novel 5-methyl-1,2,4-triazolo[1,5-a]pyrimidin-7(4H)-one-based complexes

Conventional reactions of the versatile multidentate ligand 5-methyl-1,2,4-triazolo[1,5-a] pyrimidin-7(4H)-one (HmtpO) with metallic(II) perchlorate salts lead to three novel multidimensional complexes [Cu(HmtpO)2(H2O)3](ClO4)2·H2O (1), {[Cu(HmtpO)2(H2O)2](ClO4)2 ·2HmtpO}n (2) and {[Co(HmtpO)(H2O)3](ClO4)2·2H2O}n (3). We have tested the antiparasital activity in vitro and in vivo of the three new complexes against Trypanosoma cruzi showing very promising results and overcoming clearly the reference drug commonly used for the Chagas disease treatment, benznidazole.

Three multidimensional complexes containing the nucleobase-analog 5-methyl-1,2,4-triazolo[1,5-a] pyrimidin-7(4H)-one (HmtpO), have been obtained displaying an interesting coordination behaviour for HmtpO ligand. In the three compounds, antiparasital activity in vitro and in vivo against Trypanosoma cruzi overcomes clearly the reference drug commonly used for the Chagas disease treatment, benznidazole.Figure optionsDownload as PowerPoint slide